C-AMOQCuraSen
adrenergic receptor agonists, noradrenergic restoration, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-AMOQ
C-AMOQC-AMOQadrenergic receptor agonists, noradrenergic restoration, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This is a study to evaluate the effects of CST-3056 on orthostatic symptoms and signs in subjects with neurogenic orthostatic hypotension (nOH).
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study to evaluate the effect of multiple oral doses of CST-103 in the presence of CST-107 on Freezing of Gait (FOG) symptoms in subjects with Parkinson's Disease (PD).
This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.
This study will evaluate the effects of CST-2032 when administered with pre-administered CST-107 on safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in patients with cognitive impairment.
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with Neurodegenerative Disorders.
CuraSen appoints Peter Butera as senior vice president of operations - Becker’s Spine Review Skip to main content BHR Clinical Health IT CFO ASC Spine Dental Payer Behavioral Physician About About Becker’s Careers For Sponsors Contact Us Media Kit Custom Studios Content Specs Career Center Search Subscribe Spine Spine Spinal Tech Outpatient Spine Leadership & Management Spine Leaders Practice Management Featured Insights Orthopedic Surgery Centers Orthopedic Robotics Biologics Resources Webinars & Whitepapers Podcasts Featured Content Lists Videos Newsletters Print Issues Executive C … gate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now. Emplify Health cut EHR training time for nurses by 66% — without adding classroom hours Recommended Whitepaper Advertisement Advertisement Next Up in Spinal Tech Life Spine minimally invasive implant earns FDA clearance Life Spine received FDA 510(k) clearance for its VersaLift Expandable Interbody System, a device designed for transforaminal lumbar interb
CuraSen Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas CuraSen Therapeutics Website: CuraSen Therapeutics Business Area(s) Neurobiology Alzheimer's Parkinson's Disease Small Molecules Description CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases, including Parkinson’s Di
CuraSen Therapeutics - Operations Team | The Org Platform Enrich Pricing Log in Sign up CuraSen Therapeutics Teams Operations Team Unverified Operations Team 3 people · 0 jobs The Operations Team at CuraSen Therapeutics oversees the efficient functioning of the company's daily activities, supports executive management, and manages human resources. They ensure that internal processes align with CuraSen's mission of developing innovative drugs for CNS and neurodegenerative diseases, streamlining operations to enhance productivity and organizational effectiveness. People ( 3 ) Kate No
Get the job you really want - Zippia Verifying you are human. This may take a few seconds. (Loading widget...)
Contact | CuraSen About Leadership Science Pipeline Careers News Contact Contact About Leadership Science Pipeline Careers News Contact Office Address 733 Industrial Road San Carlos CA 94070 Phone 650-475-2842 Email [email protected] © 2026 by CuraSen Therapeutics, Inc. MENU About Leadership Science Pipeline Careers News Contact
CuraSen Therapeutics Expands Management Team; Industry Veteran and Neuroscience Expert Gabriel Vargas, MD, PhD, Appointed to Chief Medical Officer Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases … D in biochemistry from the University of California, Irvine , and completed his residency and fellowship in psychiatry at the University of California, San Francisco (UCSF). In October 2018 , CuraSen announced the closing of a $54.5 million Series A financing. Key research advanced by Mehrdad Shamloo , PhD, has laid the foundation for CuraSen's programs and is licensed from Stanford University . About CuraSen CuraSen Therapeutics, Inc. is developing drugs targeting a novel me … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
News 2025 - nlvpartners Home Approach Team Portfolio About News Contact Select Page 2025 Press Releases 2026 2025 2024 2023 2022 Portfolio Companies New Leaf Portfolio Companies STAR THERAPEUTICS PRESENTS INTERIM DATA FROM PHASE 1/2 MULTIDOSE STUDY OF VGA039 IN VON WILLEBRAND DISEASE, DEMONSTRATING SUBSTANTIAL BLEED REDUCTIONS IN ALL PATIENTS, AT ASH ANNUAL MEETING December 6, 2025 Sunbird Bio Presents New Clinical Data Supporting the Accuracy of its Blood-Based Alpha-Synuclein Assay for Parkinson’s Disease Detection December 4, 2025 CuraSen Therapeutics Doses First Patient with CuraAX (CST-30
IO Biotech, Inc. (Form: DEF 14A, Received: 04/14/2022 16:02:53) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ C … ment, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Table of Contents IO BIOTECH, INC. NOTICE OF THE 2022 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD MAY 25, 2022 TO OUR STOCKHOLDERS: NOTICE IS HEREB … a unique link that will allow you access to the annual meeting and to vote and submit questions during the annual meeting. During the annual meeting, stockholders will be asked to consider the following matters, as more fully described in the proxy statement accompanying this notice: 1. the election of the Two Class I directors named in the proxy statement; 2. the ratification of the appointment of EY Godkendt Revisionspartnerselskab as our i … tents TABLE OF CONTENTS GENERAL INFORMATION 1 PROPOSAL ONE: ELECTION OF TWO CLASS I DIRECTORS 6 General 6 Information Regarding Nominees and Continuing Directors 6 Recommendation of Our Board of Directors 9 CORPORATE GOVERNANCE 10 Director Independence 10 Leadership Structure of the … p; 26 EQUITY COMPENSATION PLAN INFORMATION 27 PROPOSAL TWO: RATIFICATION OF THE APPOINTMENT OF EY GODKENDT REVISIONSPARTNERSELSKAB AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2022 28 Principal Accountant Fees and Services  
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Tate & Lyle Ventures: Funding, Team & Investors | Startup Intros Home / Organizations / … Partner About Tate & Lyle Ventures operates as a corporate venture capital fund, providing strategic investments to high-growth companies. It targets innovative businesses developing renewable ingredients and advanced food technologies, fostering breakthroughs for the food and beverage sector. The fund serves as both a financial and strategic partner to these promising enterprises, contributing expertise alongside capital. Established in 2006, Tate & Lyle Ventures wa … dership in specialized ingredient markets. Based in London, United Kingdom, the fund sought to engage promising new technologies and business models to complement its parent's core operations. The fund's portfolio companies are innovative startups and scale-ups creating novel solutions in ingredient science and food technology. Tate & Lyle Ventures accelerates the commercialization of advancements aligned with increasing global demand for healthier, tastier, and more sust … ier, tastier, and more sustainable food and drink. Through its investments, the fund actively shapes the future of global nutrition and ingredient solutions. Leadership Team 3 people Key people at Tate & Lyle Ventures . Heather Roxborough Principal DA David Atkinson Managing Partner Simon Barnes Managing Partner Deep Dive High-Level Overview Tate & Lyle Ventures is the corporate venture capital arm of Tate & Lyle PLC , a global leader in speciality food and bevera … onsumer health.[1][4] The firm manages two funds: a fully committed £25 million fund launched in 2006 and an active £30 million fund (totaling £46 million), structured as independent limited partnerships for rapid, objective decisions.[1] With 21 investments to date, including a Series B in CuraSen Therapeutics in November 2022, it targets early-
Market Research Reports and Consulting – Global Insight Services Parkinson's Disease - Drug Pipeline Landscape, 2024 US: +1-833-761-1700 [email protected] Submit Queries Home Reports Automotive & Transportation Chemicals & Materials Consumer Goods Energy & Natural Resources Food & Beverages Manufacturing & Construction Medical Devices Pharmaceuticals Semiconductors & Electronics Technology, Media, & Telecom Services Syndicated Reports Custom reports Consulting Services Subscriptions Insights Analyst Insights Press Releases Contact Us --> Hom … t the U.S. FDA has issued a complete Response Letter (CRL) for SPN-830 New Drug Application (NDA). Advanced and Investigational Treatments: MRI-Guided Focused Ultrasound (MRgFUS): A minimally invasive treatment that targets specific areas in the brain to reduce tremors. Deep Brain Stimulation (DBS): A surgical procedure where electrodes are implanted in the brain to send electrical impulses and reduce symptoms. Gene Therapy: Investigational approach aiming to correct or repla … gh primary sources, allowing for an overall market value to be derived for each application. Year-over-year (Y-o-Y) growth rates were applied to forecast market values for each application, reflecting a trend of slow, steady, or growing demand based on actual growth rates in each sector. The compound annual growth rate (CAGR) was calculated by analyzing industry penetration, supply and demand trends, and end-user industries' needs for the market. The market was further verifi … ted based on secondary research, including splits by battery voltage, type, and application. The demand from companies in different application segments was analyzed to assess overall market trends. Ongoing and upcoming projects implementing the market were tracked, and these insights were used to estimate market size based on key developments. Several discussions with industry leaders were conducted to validate the split of market segments by voltage, type, and application.
CuraSen Therapeutics Expands Management Team; Appoints Peter Butera as Senior Vice President, Operations | CuraSen About Leadership Science Pipeline Careers News Contact News CuraSen Therapeutics Expands Management Team; Appoints Peter Butera as Senior Vice President, Operations « back September 10, 2019—San Mateo, Calif.—CuraSen Therapeutics, Inc., a privately held clinical stage biotechnology company focused on developing therapies to treat neurodegenerative diseases, has appointed Peter Butera as senior vice president, operations. Mr. Butera brings more than 30 years of diverse clinic
ASPET | GPCR Colloquium Renew Join Directory Community Donate Store ( 0 ) Search Log out Log in My Profile About Us Who We Are ASPET History Bylaws ASPET Strategic Plan 2023 - 2027 Diversity, Equity, and Inclusion Code of Conduct ASPET Staff Contact Information (Members Only) ASPET Council Position Descriptions for ASPET Elected Officers ASPET Council Nominations Previous Election Results 2026 ASPET Election Results 2025 ASPET Election Results 2024 ASPET Election Results 2023 ASPET Election Results 2022 ASPET Election Results 2021 ASPET Election Results 2020 ASPET Election Results 2019 ASPET E … s Task Force Young Scientists Committee Membership & Community ASPET Membership Apply For Membership Renew Your ASPET Membership Membership Types and Dues Developing Country Dues Membership FAQs ASPET Member-Get-A-Member Contact Membership Department ASPET Member Benefits ASPETConnect Online Community Journals The Pharmacologist Get Involved with ASPET Committees Divisions Division for Behavioral Pharmacology (BEH) Executive Committee Join Our Division J.H. Woods Early Career … harmacology (BEH) Executive Committee Join Our Division J.H. Woods Early Career Award in Behavioral Pharmacology P.B. Dews Lifetime Achievement Award for Research in Behavioral Pharmacology About P.B. Dews P.B. Dews Contributions Research Resources Membership Directory News Archive Contact Us Division for Cancer Pharmacology (DCP) Executive Committee Division Awards Susan B. Horwitz Award Lecture in Cancer Pharmacology Join Our Division Membership Directory News Archive Conta … in Vascular Pharmacology Division for Cardiovascular Pharmacology Early Career Award Division for Cardiovascular Pharmacology Mid-Career Award Benedict R. Lucchesi Young Scientist Travel Award in Cardiac Pharmacology Benedict R. Lucchesi Distinguished Lectureship in Cardiac Pharmacology Division Resources Membership Directory News Archive Contact Us Division for Drug Discovery and Development (DDD) Executive Committee Join Our Division Scientific Achievement Award in Drug Di … and Disposition (DMDD) Executive Committee Join Our Division Bernard B. Brodie Award in Drug Metabolism and Disposition Brodie Award Funding Richard Okita Early Career Award in Drug Metabolism and Disposition James R. Gillette Award Membership Directory News Archive Contact Us Division for Molecular Pharmacology (MP) Executive Committee Join Our
CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases | Alta Partners About Portfolio Team Feed Connect LP Login Explore Alta Partners About Portfolio Team Feed Connect LP Login Privacy Legal Back to feed Company News | 10/18/2018 CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases Kathleen Sereda Glaub Appointed Executive Chair and
Longitude Capital: Venture Growth Investing in Healthcare ABOUT TEAM PORTFOLIO NEWS CONTACT LP LOGIN Select Page Investing in transformative healthcare companies. Strategy & Approach Longitude Capital specializes in making venture growth investments in biotechnology, medical technology, and health solutions companies that seek to improve clinical outcomes, enhance patient quality of life, and reduce the cost of care. We invest in both privately held and publicly traded companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over $2 billion across six … zes returns to key stakeholders. Our company name was inspired by the Longitude Prize , a competition established by the British monarchy in 1714 to solve one of the greatest scientific problems of the day. Our Team, Your Partners Longitude Capital’s founders have been investing together since 2002. Our team has over 200 years of combined investing experience in the life sciences industry and has collaborated on over 90 new investments and 150 follow-on investments in the bio … nt practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund and he began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis (VLTS), Hoffman – La Roche, and Novartis. Mr. Enright currently serves on the boards of BioAge Labs (BIOA), CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Opna B … to Pequot Ventures, Mr. Galletti worked at Amerindo Investment Advisors, Vector Fund Management, and the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his career in the life sciences industry at APM, a management consultancy dedicated to improving operations performance within the patient care and procedural units of large acute-care hospitals. Mr. Galletti currently serves on the board of Murj. Selected prior board memberships include … n Pharmacology from the Catholic University in Leuven, Belgium. She completed a fellowship in clinical pharmacology at Stanford University and holds an MBA from St. Mary’s College. Dr. Vanhove has authored, or co-authored, dozens of peer-reviewed articles, and is an inventor of numerous patents. — Focus Areas: Biotechnology Location: Menlo
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
DEF 14A 1 d425259ddef14a.htm DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt … ment, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Table of Contents IO BIOTECH, INC. NOTICE OF THE 2023 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 8, 2023 TO OUR STOCKHOLDERS: NOTICE IS H … a unique link that will allow you access to the annual meeting and to vote and submit questions during the annual meeting. During the annual meeting, stockholders will be asked to consider the following matters, as more fully described in the proxy statement accompanying this notice: 1. the election of the two Class II directors named in the proxy statement; 2. an amendment to the Certificate of Incorporation to provide exculpation for officers; 3. … tents TABLE OF CONTENTS GENERAL INFORMATION 1 PROPOSAL ONE: ELECTION OF TWO CLASS I DIRECTORS 6 General 6 Information Regarding Nominees and Continuing Directors 6 Recommendation of Our Board of Directors 7 CORPORATE GOVERNANCE 10 Director Independence 10 Leadership Structure of the … Y COMPENSATION PLAN INFORMATION 25 Table of Contents PROPOSAL TWO: AMENDMENT TO THE CERTIFICATE OF INCORPORATION TO PROVIDE EXCULPATION FOR OFFICERS 26 Recommendation of Our Board of Directors 27 PROPOSAL THREE: RATIFICATION OF THE APPOINTMENT OF EY GODKENDT REVISION
Portfolio Companies – ChiesiVentures Skip to content Menu Home Investment Focus Small Molecules and Biologics Advanced Therapies Reformulation Technological Platform and Devices Disease discovery, diagnosis and management Investments Portfolio Companies Strategic Connections Pappas Capital News Connect Team and Governance Submit your business plan Portfolio Companies Portfolio Companies Chiesi Ventures invests in innovative biotech companies developing treatments for rare diseases. MIRUM PHARMACEUTICALS Mirum Pharmaceuticals is developing a compound, maralixibat, to treat Alagille syndro … Companies Strategic Connections Pappas Capital News Connect Team and Governance Submit your business plan
abrdn Life Sciences Investors (Form: N-CSR, Received: 12/08/2025 16:53:00)     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM N-CSR   CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES     Investment Company Act file number: 811-06565     Exact name of registrant as specified in charter: abrdn Life Sciences Investors     Address of principal executive offices: 1900 Market Street, Suite 200   Philadelphia, PA 19103     Name and address of agent for service: Sharon Ferr … tees  (the "Board") of the abrdn Life Sciences Investors (the “Fund”) has authorized a managed distribution policy (“MDP”) of paying quarterly distributions at an annual rate, set once a year, that is a percentage of the rolling average of the Fund’s net asset values over the preceding three month period ending on the last day of the month immediately preceding the distribution’s declaration date (the "Distribution Policy"). … ains and, to the extent necessary, paid-in capital. With each distribution, the Fund will issue a notice to shareholders and an accompanying press release which will provide detailed information regarding the estimated amount and composition of the distribution and other information required by the Fund’s MDP exemptive order. The Board may amend or terminate the MDP at any time without prior notice to shareholders; however, at this time, there are no reasonably fo … cause the termination of the MDP. You should not draw any conclusions about the Fund’s investment performance from the amount of distributions or from the terms of the Fund’s MDP.   Distribution Disclosure Classification   (unaudited) The Fund’s policy is to provide investors with a stable distribution rate. Each quarterly distribution will be paid out of current income, supplemented by realized capital gains and, to the extent necessary, paid-i … ed by realized capital gains and, to the extent necessary, paid-in capital. The Fund is subject to U.S. corporate, tax and securities laws. Under U.S. tax rules, the amount applicable to the Fund and character of distributable income for each fiscal period depends on the actual exchange rates during the entire year between the U.S. Dollar and the
CuraSen Therapeutics, Inc. Company Overview, Contact Details & Competitors | LeadIQ Learn more at LeadIQ.com Start free Insights Similar companies Tech Stack Media & News Email Format FAQ Insights Innovative Therapeutic Focus CuraSen specializes in novel treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's, targeting early pathological pathways. This unique approach offers opportunities to collaborate or supply advanced research tools and compounds to accelerate drug development pipelines. Recent Funding and Strategic Investment With recent investments
Product News articles and careers information on BioSpace Skip to main content Skip to main menu Skip to user menu Jobseeker Sign in News Drug Development FDA Drug Delivery Deals Business Policy Cell and Gene Therapy Weight Loss Rare Disease Cancer Job Trends Artificial Intelligence NextGen: Top Start Ups To Watch Podcasts Reports Webinars Press Releases All News & Releases Insights Jobs Search Jobs Job Alerts Jobseeker Sign In Career Advice Companies Hotbeds More Best Places to Work Employer Resources Post Jobs Talent Solutions Advertise Submit a Press Release Subscribe Subscribe Search Jobs … Laboratories, Inc., announces that it is preparing a second business investment application in Vietnam as part of the planned expansion of its business operations. NanoMosaic launches AAV gene therapy bioprocessing and manufacturing QC assays for simultaneous capsid & transgene interrogation with high standardization 3/6/2024 NanoMosaic, the multiplex and multi-omic quantification company, announced the expanded capabilities and availability of assays optimized on its Tes … icy More Employer Login Employer Resources Post Jobs Talent Solutions Advertise Submit a Press Release RSS Feeds Facebook This will open in a new window Twitter This will open in a new window LinkedIn This will open in a new window Instagram This will open in a new window © 1985 - 2026 BioSpace.com. All rights reserved. Powered by Madgex Job Board Software
NPORT-EX 2 NPORT_TN00_5051087036.htm Tekla Healthcare Investors SCHEDULE OF INVESTMENTS June 30, 2021 (Unaudited) SHARES CONVERTIBLE PREFERRED (Restricted) (a)(b) – 5.7% of Net Assets VALUE Biotechnology – 4.1% 326,667 Amphivena Therapeutics, Inc. Series B, 6.00% $ 4,900,001 525,972 Amphivena Therapeutics, Inc. Series C, 6.00% 1,887,315 1,979,443 Arkuda Therapeuti … 4,904,185 State Street Institutional U.S. Government Money Market Fund, Institutional Class, 0.03% (f) $ 24,904,185 TOTAL SHORT-TERM INVESTMENTS (Cost $45,842,185) 45,842,185 TOTAL INVESTMENTS BEFORE MILESTONE INTERESTS - 101.5% (Cost $886,194,620) 1,190,103,560 INTERESTS MILESTONE INTERESTS (Restricted) (a)(b) - 0.9% of Net … ment Valuation and Fair Value Measurements. (c) Affiliated issuers in which the Fund holds 5% or more of the voting securities (total market value of $23,165,791). (d) Foreign security. (e) All or a portion of this security is on loan as of June 30, 2021. (f) This security represents the investment of cash collateral received for securities lending and is a registered investment company advised by State Street Global Advisors. The rate shown is the annualized seven-day y … close of trading, generally 4 p.m., Eastern Time. The Board of Trustees of the Fund (the Trustees) has established and approved fair valuation policies and procedures with respect to securities for which quoted prices may not be available or which do not reflect fair value. Convertible, corporate and government bonds are valued using a third-party pricing service. Convertible bonds are valued using this pricing service only on days when there is no sale reported. Restricted … ax purposes was $893,860,577. The net unrealized gain on securities held by the Fund was $306,897,045, including gross unrealized gain of $385,244,749 and gross unrealized loss of $78,347,704. Security Lending The fund may lend its securities to earn additional income. The fund receives collateral from the borrower in an amount not
CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease |… | Gabriel Vargas, MD, PhD | 16 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can … are pleased to announce a $5.8M investment from the Alzheimer’s Drug Discovery Fund to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease. Alpha-1A adrenoceptors are known to help regulate neurotransmission and are prevalent in the areas of the brain important to memory and learning, making them a promising target for Alzheimer’s drug development. https://lnkd.in/g2a6A4vF CuraSen Therapeutics Announces Strategic Investment fr
CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium | CuraSen About Leadership Science Pipeline Careers News Contact News CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium « back Data support ongoing Phase 2a study with CuraAX in patients with neurogenic orthostatic hypotension (nOH) to prevent severe decreases in
%PDF-1.7 %���� 1 0 obj >stream x����� �]�U�+� endstream endobj 2 0 obj >]/Intent/Perceptual/Subtype/Image/Height 1004/Filter/FlateDecode/Type/XObject/Width 1003/SMask 1 0 R/Length 50324/BitsPerComponent 8>>stream x�����w����w��=�wΞsfwg3����C�{ �� RI������^H! I(w�`�&[�r�l�E��e�r��\���0��������z>�7wmI�|ז��W 3::�����h�x�**�KKc�1�sȴ�2X�a-��0�n�Ӛ��j�����}��G ��.c�1�cL�g ~�Er��t�����5k�n�a�1�c�����g-�ӽ��k?��c�1�c MKh-�3��}�h�� ;c�1�c�N�i-�3S�M��� /c�1�c6���f�{yI����c�1Ƙm��I�~df&?;[�d�1�c�f�2[�m�~�Ν��7|�i��/�ܱ}{^v����c�1� 2��w��Ö͛�$^|?k�ml� :p`1ﶯ�.-.���1�oT�����Z$/ … 0 0 1]/Border[0 0 0]/Rect[543.28 780.87 588.28 735.87]>> endobj 4 0 obj >stream application/pdf doi:10.1002/mds.28067 10.1002/mds.28067 https://doi.org/10.1002/mds.28067 2020-04-16 true onlinelibrary.wiley.com 10.1002/mds.28067 onlinelibrary.wiley.com true 2020-04-16 10.1002/mds.28067 endstream endobj 5 0 obj >stream x�+��| endstream endobj 6 0 obj >stream x�S�*�*T01U0B ejb�gd�`nl�ga����� �i�������t � endstream endobj 9 0 obj >stream hޜ{ے�F����[}E��8��p \l ��U��j��jUez) … 8AJxV3+gf5OKu/0D/JxV3+gf5OKu/0D/JxVcn1
Kvw8a4qiBSm3TFXYq7FXYq7FXYq7FX//2Q== application/postscript MDS_33-04_Cover1.indd admin xmp.did:7f784ea0-88cf-8a4c-b841-13f5e39ac92a xmp.iid:7f784ea0-88cf-8a4c-b841-13f5e39ac92a uuid:e1a47b11-7282-45dc-99b2-92f57eca6e62 uuid:d162efe3-4f9e-42f9-8b4e-b6c8e3bf7321 uuid:e1a47b11-7282-45dc-99b2-92f57eca6e62 uuid:e1a47b11-7282-45dc-99b2-92f57eca6e62 saved xmp.iid:7f784ea0-88cf-8a4c-b841-13f5e39ac92a 2018-06-04T21:15:38+05:30 Adobe Illustra … 4+LIYwyCz0+ys04WsCQr34AAn5
nqc2+LBDGKgAGYFK+WpdirsVdirsVdirsVdirsVdir//2Q== application/postscript saved xmp.iid:40338E756D63E411A01CE06922E7E506 2014-11-05T17:29:33+05:30 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:6915BBD94C60E611AD72B662A92B5C94 2016-08-12T10:53:06+05:30 Adobe Illustrator CS6 (Windows) / converted from applicat … 5:30 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3548084a-5e0c-d64a-b180-1776fcb21313 2017-01-09T12:47:32+05:30 Adobe Illustrator CC 2014 (Windows) / saved xmp.iid:bc1ba4e7-2a58-734c-a255-c04fb17861f2 2017-01-09T12:47:36+05:30 Adobe Illustrator CC 2014 (Windows) / xmp.
You need to enable JavaScript to run this app. Loading...
N-CSR 1 tm2430035d6_ncsr.htm N-CSR       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM N-CSR   CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES   Investment Company Act file number:   811-06565       Exact name of registrant as specified in charter:   abrdn Life Sciences Investors       Address of principal executive offices:   1900 Market Street, Suite 200     Philadelphia, PA 19103       Name and address of agent for service: … the Board of Trustees (the "Board") of the abrdn Life Sciences Investors (the "Fund") approved the continuation of the managed distribution policy ("MDP") and determined to increase the rolling distribution rate from 8% to 10% based on the average daily net asset value of the previous three months as of the month-end prior to declaration for the 12-month period commencing with the distribution paid on March 28, 2024. In May 2024, the Board determined to increase the rolling … r to declaration commencing with the distribution payable on June 28, 2024. The Fund intends to maintain the increased MDP for at least 12 months from the distribution payable date unless there is significant and unforeseen change in market conditions. With each distribution, the Fund will issue a notice to shareholders and an accompanying press release which will provide detailed information regarding the estimated amount and composition of the distribution and other in … mount and composition of the distribution and other information required by the Fund’s MDP exemptive order. The Board may amend or terminate the MDP at any time without prior notice to shareholders; however, at this time,there are no reasonably foreseeable circumstances that might cause the termination of the MDP. You should not draw any conclusions about the Fund’s investment performance from the amount of distributions or from the terms of the Fund’s MD … 019;s MDP.   Distribution Disclosure Classification   (unaudited) The Fund’s policy is to provide investors with a stable distribution rate. Each quarterly distribution will be paid out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital. The Fund is subject to U.S. corporate, t
%PDF-1.7 %���� 144 0 obj > stream endstream endobj 145 0 obj > stream jP � ftypjp2 jp2 jpxbjpx rreq���@ .-jp2hihdr%�colr�jp2c�O�Q)�%�%�R �\@@HHPHHPHHPHHPHHP�� $��ϴ \��������� ����P���O��D�T�+kH� �_KX~3 F�f7�*�� Y�l� �o�l�����0 �Ŧ�� c��?��}Ƿ�P�����3�dQ���X؊2s/m�l�N�]߀X'���] ����m {/�8��R��r4��� ������ ��T?,{]N ��K�JI��)���͆�z�V5�#�碘�5��҆He�%�{��rë���ʆ?;?�� ������_�S�$���ޤ ct! �/� ��UZ�����ey��!�G�xϬ�Z֎ � V �Ͽ���[�U�`��08*�\P�5|�ϱ�o���A�XrZ��?���EK o��S,+5�%����G�˒0؛���� 7ʐ���6%��R���!H��~�̛�,~U���q1��G�q�� U�5 ��ERN],%1�lbn … xA; 
 
 
 
 2024-10-23T08:36:28-07:00 2024-10-24T09:45:39-04:00 application/pdf uuid:8c1ee4a2-905e-4446-8a64-72eeae2a7082 uuid:8f1ea714-003a-4994-bf90-898f25dc11b2 endstream endobj 194 0 obj > stream H��W�n�H��z[ka�U�l��`�\��=�� 6�!=��8�M$Ob���U$KŒJv2yZ4Б������������_�⧟���r��)��xQ�������/q7K��e"W�Tj*&�LN&��'�L��^ ����,�ͳ/���r�+��]U������r��-b���^�D����3�E�eR_�xw��h���s��Au�F�������~��h�?�ªE�� ��d ߮�����|���E�bǩX�=�J�̘���ꍣ�� �|�[bXmV&2M�1+V
CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease | CuraSen About Leadership Science Pipeline Careers News Contact News CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease « back October 9, 2023, San Mateo, CA – CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies … gh the generosity of its donors, the ADDF has awarded more than $270 million to fund over 730 Alzheimer’s drug discovery programs, biomarker programs and clinical trials in 19 countries. To learn more, please visit: http://www.alzdiscovery.org/ . About Alzheimer’s Disease Alzheimer’s is a progressive, neurodegenerative disease and the most common cause of dementia. An estimated 50 million people are living with dementia worldwide. In its early stages, Alzheimer’s
CuraSen Therapeutics Announces $54.5 Million Series A Financing - Pappas Capital Aktis Oncology Reports First-in-Human Clinical Imaging… BOSTON, May 21, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including... Read More Investor Login Toggle navigation Home About About Us News & Events For Entrepreneurs Contact Us Team Portfolio Ventures Specialized Fund Management About Chiesi Ventures Fund Asia Innovation Ventures Ag
Live Team Training for Parkinson's 2025 | Parkinson's Foundation Learning Lab Jump to content Parkinson's Foundation Learning Lab Search Open menu Cart My Courses Log in Register Bookmark/Search this post Facebook X LinkedIn Forward Home Education Hubs Professional Education Live Professional Education Community Education Volunteer Education Formación en español Special Programs Team Training *NEW* Student Corner Community Partners in Parkinson's Care Edmond J. Safra Nurse Educator Program Exercise & Movement Education Accreditation Recognition Tools and Resources Español About You ar … and late stages of Parkinson’s disease to guide appropriate care interventions. Apply team care strategies to support individuals with Parkinson’s and their care partners in improving self-management and quality of life. Engage in interprofessional collaboration to optimize care coordination and improve outcomes for people with Parkinson’s and their care partners. Strengthen interprofessional networks and community partnerships to enhance the delivery of comprehensive team-ba … re. Commercial Support Disclosure: This activity is supported by an educational grant from Amneal Pharmaceuticals, Inc. Course summary Available credit: 27.00 AAPA Category I CME 27.00 AMA PRA Category 1 Credit ™ 27.00 ANCC 27.00 APA 2.60 ASHA CE 27.00 ASWB ACE 27.00 IPCE Credit™ 27.00 Occupational Therapist 27.00 Participation 27.00 Physical Therapist Course opens: 04/28/2025 Course expires: 11/30/2025 Event starts: 10/20/2025 - 7:00am EDT … ation has been authorized by the American Nurses Credentialing Center (ANCC) to award CNE credit. This activity is designated for 27.00 CNE credits. Participants should only claim credit commensurate with the extent of their participation. Physician Assistants Parkinson’s Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 27.00 AAP
CuraSen Therapeutics Expands Management Team; Industry Veteran and Neuroscience Expert Gabriel Vargas, MD, PhD, Appointed to Chief Medical Officer | CuraSen About Leadership Science Pipeline Careers News Contact News CuraSen Therapeutics Expands Management Team; Industry Veteran and Neuroscience Expert Gabriel Vargas, MD, PhD, Appointed to Chief Medical Officer « back SAN MATEO, Calif., Nov. 1, 2018 /PRNewswire/ — CuraSen Therapeutics, Inc., a privately held biotechnology company focused on developing therapies to treat neurodegenerative diseases, today announced that it has a … hD in biochemistry from the University of California, Irvine, and completed his residency and fellowship in psychiatry at the University of California, San Francisco (UCSF). In October 2018, CuraSen announced the closing of a $54.5 million Series A financing. Key research advanced by Mehrdad Shamloo, PhD, has laid the foundation for CuraSen’s programs and is licensed from Stanford University. Contact Susan Kinkead Kinkead Communications [email protected] 415-509-361
Loretta Tse, Ph.D. - Biocom Skip to main content Search Cancel Select Location Choose a location San Diego Greater Los Angeles Bay Area Seattle Sacramento Washington, D.C. Tokyo Enter your location ZIP Code Submit Location Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podcast Episodes About About Us Our Team Board of Directors Careers Contact Our Locations San Diego Grea … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Membership Member Benefits Become a Member Conference & Events Funding & Partnering Group Purchasing Policy & Advocacy Workforce Development International Connections Increase Visibility Community Building Catalyst: Innovators Under 40 CEO/Founder Network Converge … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podc … n associate at Oxford Biosciences Partners, an early-stage life science venture fund, and worked in business development at several early-stage biotech companies prior to joining Oxford. She holds a Ph.D. in pharmacology from Johns Hopkins School of Medicine and a B.S. in biochemistry from University of California, Davis. Loretta has invested in over 20 life sciences companies and is currently on the BOD of CuraSen and HotSpot Therapeutics. Join About Us Our Team Board of Dir
Simon Tate, PhD | CuraSen About Leadership Science Pipeline Careers News Contact Board of Directors Simon Tate, PhD « back Simon is a Managing Director at Intermediate Capital Group (ICG) and has 32 years of experience in R&D. He has spent most of his career working in the fields of Pain and Neuroscience. He was one of the founders of Convergence Pharmaceuticals, and as Chief Scientific Officer and head of R&D, he led Convergence to its successful acquisition by Biogen for $675M in 2015. Following this acquisition, Simon joined Biogen, where he assumed the role of Vice President
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Gabriel Vargas, MD, PhD | CuraSen About Leadership Science Pipeline Careers News Contact Leadership Gabriel Vargas, MD, PhD « back Dr. Vargas joined CuraSen in October 2018, bringing more than 12 years of pharmaceutical research and development experience, focused on translational medicine, early clinical development and neuroscience. At Amgen, he most recently held the position of executive medical director, digital health and neuroscience therapeutic area head for early development, and was responsible for the neuroscience portfolio strategy from preclinical research through early deve … hD in biochemistry from the University of California, Irvine, and completed his residency and fellowship in psychiatry at the University of California, San Francisco. © 2026 by CuraSen Therapeutics, Inc. MENU About Leadership Science Pipeline Careers News Contact
Michael P. Dillon, PhD | CuraSen About Leadership Science Pipeline Careers News Contact Leadership Michael P. Dillon, PhD « back Dr. Dillon joined Curasen in January 2023 bringing more than 30 yrs of research and development experience across large and small pharmaceutical companies. Most recently, Dr. Dillon was chief scientific officer and head of research at IDEAYA Biosciences, where he was responsible for establishing the drug discovery strategy, building the team, and selecting the early portfolio. Under his leadership, IDEAYA established itself as one of the leading Synthetic Letha … Ph.D. from the University of Bristol, in the UK. He completed his postdoctoral fellowship in chemistry at Oregon State University. Dr. Dillon is an author of more than 70 publications and patents. © 2026 by CuraSen Therapeutics, Inc. MENU About Leadership Science Pipeline Careers News Contact
CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease | CuraSen About Leadership Science Pipeline Careers News Contact News CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease « back Increased Cerebral Blood Flow is Correlated with Increased Neuronal Activity and Cognitive Efficacy Signals Data Presented at the 14th
%PDF-1.7 %���� 4731 0 obj > stream x��Z[S�F~�W��f��{k+�*�� Y��d�8 �n"�"�Md�4������ 5$�JQ��O�L?'bRJ������) �S3�>3��%���sX�g�p���[�dL�@A�#��*-��` %54�X-!��� �� ƀ9���ԈHV��,� ����Lp ��0!i2H �dńu4G2���I�i9�́�T��p��7��5&�F����!Ŕ!-8�p1�Ls�Ù�$*���`_� �Mc)ld4,�`%c 54��h�0&�q� Ms8b@&C: %M �2��B�b#p��AC� 24���d���V� X^� G=��H� B�94��4V H` ��$:��!@��kH`5Aݭ���VC ݭ��[ ���74t���@wG� Ɗ� ;jD�9B �;N�ݝ�=tw�P�0' ,� ���� ᜶��;C����hj��!SBw��Cw��@�8���cN^ bNF������b�1�}�{���� .�}F]?������7y~D|~n�؇��A�i�aچm��5Ɇ"�P��c� =W� ��f�Q>}� … :14562467-ed52-4613-8486-e877a774d8b6 uuid:f9e53f4b-4e79-4d94-b3c8-deee3f53dd16 application/pdf 
 
 
 
 
 
 
 
 
 
 
 
 Judy Reynolds Adobe PDF Library 21.11.71 endstream endobj 189 0 obj > stream H��Wio�H��_� Ʌ�b�&&�#�d�d��fe��%��H�֦�ѿ��>���� �lvW���^]M.Ɨ��f9���ի�e����j���I�g������4K�(����i��,�i� h���L�_0��a�M��5�Tj�ڲ�W �@9B��߅!33 M�W/?����R@��(�d���: a� ��L�� �A/������RH2WX��.��^�Y>!�H��R��Tg� m ��(���&$�/��
CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Eve … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment December 19, 2022 | 5 min read Twitter LinkedIn Facebook Email Print C … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Com … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search CuraSen NEWS JOBS NEWS Business Three Biopharma Companies Bolster Leadership Teams Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams. February 23, 2022 · 2 min read · Alex Keown Business Top Life Sciences Startups to Watch … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial February 20, 2025 | 4 min read Twitter LinkedIn Facebook Email Print CuraAX Designed to Treat Neurogenic Orthostatic Hypotension (nOH) and Cognitive Impairment SAN CARLOS, Calif.--(BUSINESS WIRE)--CuraS … gh the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery and development programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: https://www.alzdiscovery.org/ Contacts Susan Kinkead Kinkead Communications [email protected] 415-509-3610 Twitter LinkedIn Facebook Email Print California Phase 1 CuraSen LATEST Mergers & acquisitions BIO 2026: Forget dual track—biopharma deals … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCR … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease November 9, 2021 | 5 min read Twitter LinkedIn Facebook Email Print CuraSen Therapeutics, Inc. … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Ev … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease September 7, 2022 | 4 min read Twitter LinkedIn Facebook Email Print … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Relea … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference March 30, 2023 | 5 min read Twitter LinkedIn Facebook Email Print CuraSen The … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen Therapeutics Expands Management Team; Appoints Peter Butera as Senior Vice President, Operations - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business CuraSen Therapeutics Expands Management Team; Appoints Peter Butera as Senior Vice President, Operations September 10, 2019 | 3 min read Twitter LinkedIn Facebook Email Print CuraSen Therapeutics, Inc., a privately held clinical stage biotechnology company focused on developing therapies to t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SU … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease October 9, 2023 | 3 min read Twitter LinkedIn Facebook Email Print CuraSen Therapeutics, Inc. announced that it ha … gh the generosity of its donors, the ADDF has awarded more than $270 million to fund over 730 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 19 countries. To learn more, please visit: http://www.alzdiscovery.org/ . About Alzheimer’s Disease Alzheimer's is a progressive, neurodegenerative disease and the most common cause of dementia. An estimated 50 million people are living with dementia worldwide. In its early stages, Alzheimer’s disease ofte … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen Therapeutics Expands Management Team; Industry Veteran and Neuroscience Expert Gabriel Vargas, MD, PhD, Appointed to Chief Medical Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Ma … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business CuraSen Therapeutics Expands Management Team; Industry Veteran and Neuroscience Expert Gabriel Vargas, MD, PhD, Appointed to Chief Medical Officer November 1, 2018 | 2 min read Twitter LinkedIn Facebook Email Print CuraSen Therapeutics, Inc. today announced that it has appointed Gabriel Varga … D in biochemistry from the University of California, Irvine , and completed his residency and fellowship in psychiatry at the University of California, San Francisco (UCSF). In October 2018 , CuraSen announced the closing of a $54.5 million Series A financing. Key research advanced by Mehrdad Shamloo , PhD, has laid the foundation for CuraSen's programs and is licensed from Stanford University . About CuraSen CuraSen Therapeutics, Inc. is developing drugs targeting a novel me … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Unlocking opportunities that have a positive impact on families’ lives - ICG Clients Who we are What we do Sustainability People News & insights Shareholders & Debtholders Menu Careers Client Lounge Contact us Intralinks Subscribe Search We invest globally. We grow businesses sustainably. We value partnerships. Who we are Overview Our purpose & business Our offices Asia Pacific Europe Middle East North America Our history Leadership & governance Annual reports Board & committees Executive directors Policies & disclosures Sustainability reports Our values Corporate social re
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
About | CuraSen About Leadership Science Pipeline Careers News Contact About About Leadership Science Pipeline Careers News Contact It’s time to think again about therapies for psychiatric and neurodegenerative disease. At CuraSen, we are targeting these brain diseases with novel science and treatments so patients can THINK, AGAIN. CuraSen Therapeutics is a privately funded biopharmaceutical company pursuing development of novel treatments, targeting a unique mechanism of action, that can viably treat a broad range of psychiatric and neurodegenerative symptoms along with positive impact on und
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
CuraSen Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 03 Jun 2026 CuraSen Therapeutics, Inc. Startups | Holding Company | 2016 | California, United States | 10-50 | www.curasen.com Startups | Holding Company | 2016 | California, United States | 10-50 | www.curasen.com Last update 03 Jun 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Other Diseases Cardiovascular Diseases Small molecule drug Chemical drugs … gh the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery and development programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: https://www.alzdiscovery.org/ Phase 1 Phase 2 15 Oct 2024 · www.biospace.com CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer Expands Adrenergic Pipeline to Address Neurogenic Orthostatic Hypotension and Major Depressive Disor … atment for neurogenic orthostatic hypotension (nOH). The company is planning to submit an investigational new drug (IND) application this quarter. A significant orphan indication affecting approximately 120,000-150,000 patients in the U.S., nOH is a dysfunction in the autonomic nervous system common in Parkinson’s disease (PD) and related diseases that causes sudden drops in blood pressure upon standing. This can lead to debilitating dizziness, weakness, cognitive decline and … e function and mood, as well as safety and tolerability. CuraSen is planning to submit an IND application by the end of 2024 for its third drug candidate CuraAX, an α 1A -AR agonist, for the treatment of nOH. For more information, please visit . Contacts Susan Kinkead Kinkead Communications [email protected] 415-509-3610 Phase 2 Executive Change Acquisition 100 Deals associated with CuraSen Therapeutics, Inc. Login to view more data 100 Translational Medicine associated w … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
C-Path Welcomes CuraSen As Newest CPP Member Skip to content Want to stay in the know? Sign up for email updates . What We Do Programs Initiatives GEM-PD NAMs-DC One to Millions Europe Events Media Tools & Platforms --> Give News C-Path Welcomes CuraSen As Newest CPP Member August 12, 2024 --> C-Path is thrilled to welcome CuraSen Therapeutics as the newest member of its Critical Path for Parkinson’s Consortium. CuraSen is a pioneering biopharmaceutical company dedicated to developing novel treatments for neurodegenerative diseases like Parkinson’s and Alzheimer’s. Their innovative approac
Kerato Signs Exclusive Global License for LiQD Cornea | BSF Enterprise posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre
CST-2140 by CuraSen Therapeutics for Orthostatic Hypotension: Likelihood of Approval Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs F
The 20-Year Industry Secret: Redefining Neurodegenerative Treatment | Power Blog Blog Podcast Get a Demo Podcast Episode 49 The 20-Year Industry Secret: Redefining Neurodegenerative Treatment with Dr. Gabriel Vargas · Chief Medical Officer, CuraSen Therapeutics Dr. Gabriel Vargas, CMO of CuraSen Therapeutics, explains why targeting the adrenergic system — rather than amyloid plaques or depleted neurotransmitters — may offer both symptomatic relief and disease-modifying potential for Alzheimer's and Parkinson's. And why after 30+ years of anti-amyloid trials, the cognitive results sti
Curasen: Shifting the focus from just dopamine – The Science of Parkinson's Skip to content The Science of Parkinson's Plain English information about the research being conducted on Parkinson's Menu About Alpha Synuclein Dopamine Genetics of PD Lectures Previous posts Tremor What is Parkinson’s? Curasen: Shifting the focus from just dopamine December 8, 2020 December 27, 2020 ~ Simon # # # # In September, a small biotech company called CuraSen announced that they had dosed the first participant in a clinical trial of their new experimental drug for Parkinson
CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRI … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium November 10, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Data support ongoing Phase 2a study with CuraAX … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Business Takeda enters transitional year as new CEO seeks return to growth June 24, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities an … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer October 15, 2024 | 5 min read Twitter LinkedIn Facebook Email Print Expands Adrenergic Pipeline to Address Neurogenic Orthostatic Hypotension and Major Depressive Disorder in Older Adults SAN CARLOS, Calif.--(BUSINESS … atment for neurogenic orthostatic hypotension (nOH). The company is planning to submit an investigational new drug (IND) application this quarter. A significant orphan indication affecting approximately 120,000-150,000 patients in the U.S., nOH is a dysfunction in the autonomic nervous system common in Parkinson’s disease (PD) and related diseases that causes sudden drops in blood pressure upon standing. This can lead to debilitating dizziness, weakness, cognitive decline and … e function and mood, as well as safety and tolerability. CuraSen is planning to submit an IND application by the end of 2024 for its third drug candidate CuraAX, an α 1A -AR agonist, for the treatment of nOH. For more information, please visit www.curasen.com . Contacts Susan Kinkead Kinkead Communications [email protected] 415-509-3610 Twitter LinkedIn Facebook Email Print People CuraSen LATEST Pancreatic cancer Revolution’s second RAS blocker doubles chemo response rate … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen Therapeutics Expands Management Team; Appoints Peter Butera as Senior Vice President, Operations Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedi … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
With $54 Million in Hand, Startup CuraSen Takes Aim at Parkinson’s and Alzheimer’s - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business With $54 Million in Hand, Startup CuraSen Takes Aim at Parkinson’s and Alzheimer’s October 17, 2018 | 2 min read | Alex Keown Twitter LinkedIn Facebook Email Print San Mateo, Calif.-based startup CuraSen Therapeutics surged forward this morning with $54.5 million in Series A fund … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Very proud of the CuraSen team - impactful data, addressing the huge unmet need in treating cognitive decline in AD & PD patients. | Anthony Ford LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn B
Pipeline | CuraSen About Leadership Science Pipeline Careers News Contact Pipeline About Leadership Science Pipeline Careers News Contact IND-enabling Phase 1 Phase 2a Phase 2b Phase 3 CuraAX nOH in Parkinson’s & related conditions α 1A -AR agonist NCE CuraCN Neurodegenerative Disease Combo β 2 -AR agonist CuraXN Neurodegenerative Disease Combo β 2 -AR agonist NCE CuraAX IND-enabling Phase 1 Phase 2a Phase 2b Phase 3 nOH in Parkinson’s & related conditions α 1A -AR agonist NCE CuraCN IND-enabling Phase 1 Phase 2a Phase 2b Phase 3 Neurodegenerative Disease Combo β 2 -AR ago
%PDF-1.6 %���� 1 0 obj >/OCGs[11 0 R]>>/Pages 3 0 R/Type/Catalog>> endobj 2 0 obj >stream application/pdf NIF Agenda 2024-01-06T22:53:34+02:00 2024-01-06T22:53:34+02:00 2024-01-06T22:53:34+03:00 Adobe Illustrator 26.5 (Windows) 208 256 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgBAADQAwER
AAIRAQMRAf/EAaIAAAAHAQEBAQEAAAAAAAA … +̀C����s�9 cN��c�V8����Y�&}z��8�\%f�8 �V�?(�eB���g��/A`k% �?���q�0n�V�*rFP �Xf #gh[g�.rFx= G�8j�|rK�pO�����3�tȖ �"g��i���Ap䌮���d�:LC���9c�b U|�b��LF'a� hrq��34'�� ��� g���B$A�}#� �8�2 �Y�/�ϞhX���s�A�k %s���Οh�qd�._����3"̻ ?N����o W�6��q��0 ,��*�ʋT��� X?�Kq�(]� �a�_k���(5㌓�����kV/� W�q�u�5ae��Y2Θ�T5��v�i��o\p�%�wD%j D���e�a�p/_s���(P�d�z�}Hahz1�(���3�)�3Ⱥ�y���qƚ�Q e- �Za� �8�y�a���W��3�g���- . ���7x���"9#52*p���na�[�̐�r��֎���Z6�z)2
Careers | CuraSen About Leadership Science Pipeline Careers News Contact Careers About Leadership Science Pipeline Careers News Contact CuraSen is re-thinking treatments for neurodegenerative disease. We are seeking motivated, passionate and talented employees who, like our team , can think outside the box, possess an entrepreneurial spirit, strong work ethic and sense of humor. Please see below for job postings . We provide employees with a comprehensive and competitive benefits package that includes medical, dental, vision and life insurance as well as a flexible spending account for either
Science | CuraSen About Leadership Science Pipeline Careers News Contact Science About Leadership Science Pipeline Careers News Contact CuraSen is focused on activating innate homeostatic pathways via multiple cell types to restore and preserve brain health. Some of the earliest signs of neurodegeneration (anosmia, constipation, dysautonomia, sleep dysregulation), seen in Alzheimer’s, Parkinson’s and other diseases, as well as cognitive loss and depression in older adults, occur due to profound neuronal pathology in the locus coeruleus. This important brain stem nucleus is the origin of most a
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Careers | CuraSen About Leadership Science Pipeline Careers News Contact Careers About Leadership Science Pipeline Careers News Contact CuraSen is re-thinking treatments for neurodegenerative disease. We are seeking motivated, passionate and talented employees who, like our team , can think outside the box, possess an entrepreneurial spirit, strong work ethic and sense of humor. Please see below for job postings . We provide employees with a comprehensive and competitive benefits package that includes medical, dental, vision and life insurance as well as a flexible spending account for either
Home | CuraSen About Leadership Science Pipeline Careers News Contact Think, Again Rethinking Brain Disease © 2026 by CuraSen Therapeutics, Inc. MENU About Leadership Science Pipeline Careers News Contact
CuraAX - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 11 Apr 2026 CuraAX Last update 11 Apr 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms CST 3056, CST-3056 Target α1A-AR Action agonists Mechanism α1A-AR agonists(Alpha-1a adrenergic receptor agonists) Therapeutic Areas Nervous System Diseases Cardiovascular Diseases Other Diseases Active Indication Neurogenic Orthostatic Hypotension Alzheimer D … gh the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery and development programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: https://www.alzdiscovery.org/ Phase 1 Phase 2 15 Oct 2024 · www.biospace.com CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer Expands Adrenergic Pipeline to Address Neurogenic Orthostatic Hypotension and Major Depressive Disor … atment for neurogenic orthostatic hypotension (nOH). The company is planning to submit an investigational new drug (IND) application this quarter. A significant orphan indication affecting approximately 120,000-150,000 patients in the U.S., nOH is a dysfunction in the autonomic nervous system common in Parkinson’s disease (PD) and related diseases that causes sudden drops in blood pressure upon standing. This can lead to debilitating dizziness, weakness, cognitive decline and … e function and mood, as well as safety and tolerability. CuraSen is planning to submit an IND application by the end of 2024 for its third drug candidate CuraAX, an α 1A -AR agonist, for the treatment of nOH. For more information, please visit . Contacts Susan Kinkead Kinkead Communications [email protected] 415-509-3610 Phase 2 Executive Change Acquisition 07 Mar 2024 · www.biospace.com CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data
Get the job you really want - Zippia Verifying you are human. This may take a few seconds. (Loading widget...)
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders CuraSen Therapeutics: Funding, Team & Investors | Startup Intros Home / Organizations / Cura
News | CuraSen About Leadership Science Pipeline Careers News Contact News About Leadership Science Pipeline Careers News Contact Please click on the links below to read the latest news releases from CuraSen. November 10, 2025 CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium View Release October 23, 2025 CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study View Release February 20, 2025
CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
News – Page 22 – ChiesiVentures Skip to content Menu Home Investment Focus Small Molecules and Biologics Advanced Therapies Reformulation Technological Platform and Devices Disease discovery, diagnosis and management Investments Portfolio Companies Strategic Connections Pappas Capital News Connect Team and Governance Submit your business plan News Chiesi Ventures News Eventi Sort by date Sort by name Descending Ascending CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer Chiesi Ventures News March 24, 2025 October 15, 2024 Expands Adrenergic Pipeline to Add … Companies Strategic Connections Pappas Capital News Connect Team and Governance Submit your business plan
Careers | CuraSen About Leadership Science Pipeline Careers News Contact Careers About Leadership Science Pipeline Careers News Contact CuraSen is re-thinking treatments for neurodegenerative disease. We are seeking motivated, passionate and talented employees who, like our team , can think outside the box, possess an entrepreneurial spirit, strong work ethic and sense of humor. Please see below for job postings . We provide employees with a comprehensive and competitive benefits package that includes medical, dental, vision and life insurance as well as a flexible spending account for either
nadolol (CST-107) / CuraSen Therap nadolol (CST-107) / CuraSen Therap - LARVOL DELTA Home Next Prev 1 to 25 Of 30 Go to page 1 2 December 02, 2024 CLIN-011: A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders (clinicaltrials.gov) - P2 | N=41 | Completed | Sponsor: CuraSen Therapeutics, Inc. | Active, not recruiting ➔ Completed Trial completion • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Lewy Body Disease • Mental Retardation • Movement Disorders • Parkinson's Disease • Psychiatry • REM Sleep Behavior
%PDF-1.7 %���� 3539 0 obj > stream x��X�n 7��W� �!Y �$�� ŧ '0|��\��~��������"Uw�W��]=�3�� ��� ���Ef5R IЌ��Ԑ�� �r@ HḦ�ar �dF Xݐ@�9дc`6#J�d�#!�C�D�+b(da肥$3r�`�c �T3�Jz?V�()'��>��a&c$}��t/��;�(1��=C����Sy� �Չ}!�{�O�.ͩ�=�� X�������eE��Zͩ�#ZEH� �"�0r� ���e/X��U ���^E�d$��!S�{������xF�Ny��Y\�*��E��������ʭ^]Lj�3���ZA�D�f��3�4�ΐ�����;CZg�ΐ�����~�^���X�X/���e�zF�uӇZʵ���beq��'�O��|I��^4(�p�Gu��j5���U���j �3&� ��)��a8����� ����٘���c ��x�ԋ �k�� ��Ѕ�A=r|��>�+}��g^��_1/��RP�).�(.�z���������o�� ��;��e� {,�7�jW�����${�k��;�{� i~�7 �1�6F�L:�ٙw6�� … :4ec658e0-8d0f-4337-85bd-8421705afdc3 uuid:9dd3caaf-d5f6-4fbd-9fc4-7516df64d61b application/pdf 
 
 
 
 
 
 
 
 
 
 
 
 Adrienne Groulx;Melanie Buitendyk Adobe PDF Library 24.3.212 endstream endobj 3555 0 obj > stream x��Zks۶��_��ɤ��7��tF~$q�8��4�u����wd�CQi���Y�� Zt��NF֊��`�`����,˘� �B�[3n�[1a��$��~ ��7g��wƴ�L(ˌ�oÌ�o�lFߊYEߒ9i�-���͙��Oe�g�Ƅ\��V, P� ��θ� \9 �Z@�hc���6�B�Sn �@G �e�S����FӒH��jꎱ�v��KC��C 4-Z�������
CST-2032 / CuraSen Therap CST-2032 / CuraSen Therap - LARVOL DELTA Home Next Prev 1 to 16 Of 16 Go to page 1 March 07, 2024 CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD 2024 International Conference (Businesswire) - P2a | N=64 | NCT05104463 | Sponsor: CuraSen Therapeutics, Inc | "CuraSen Therapeutics, Inc...announced that it will present additional positive Phase 2a data with its combination adrenergic activator, CST-2032/CST-107...The oral presentation will take place at
CuraSen begins Phase IIa trial for neurogenic orthostatic hypotension Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Produc
intoDNA Forms Strategic Advisory Board with Leading Diagnostics and Precision Oncology Experts - intoDNA Our technology About the STRIDE® Platform DNA Damage Detection STRIDE® Assays DNA Damage Response Functional STRIDE® Assays STRIDE® Signal to γH2AX Comparison Services STRIDE® Solutions & Services Case Studies Company About Us Climate Action & Our Science-Based Target Careers Newsroom Resources Contact Our technology About the STRIDE® Platform DNA Damage Detection STRIDE® Assays DNA Damage Response Functional STRIDE® Assays STRIDE® Signal to γH2AX Comparison Services STRIDE® Solut … arch. He holds an MD and PhD from the Yale School of Medicine and completed his residency at Memorial Sloan-Kettering Cancer Center. Mike Dillon, PhD – CTO at CuraSen Therapeutics: With more than 30 years of experience in large pharma and biotech, Dr. Dillon previously served as CSO at Modifi Bio (acquired by Merck in 2025) and as Head of Research at IDEAYA Biosciences. At IDEAYA, he helped establish the company as a leader in Synthetic Lethal Oncology with a focus on DNA Dam … iversity and her MD from the University of Michigan. She completed her oncology fellowship at Stanford University and served as Assistant Professor of Medicine at Dana-Farber Cancer Institute. Scott K. Pruitt MD, PhD – Clinical and Translational Oncology Consultant: Dr. Pruitt recently retired from Merck, where he led Translational Oncology and served as Clinical Director for the pivotal Keynote-158 trial, contributing to seven FDA approvals for Keytruda. His work included pi … other articles Feb 02, 2026 intoDNA Honored with the 2025 Supplier Recognition Award by Scientist.com Keep Reading Mar 31, 2026 intoDNA to Present Two Poster Presentations at the 2026 AACR Annual Meeting Keep Reading Dec 20, 2021 intoDNA awarded funding from the Polish Agency for Enterprise Development Keep Reading Interested in compatibility of STRIDE® and human in vivo material ? The poster showcases the compelling results of our collaboration with AstraZeneca: validation … th us and we will deliver the material to your inbox: By checking this box, you grant intoDNA S.A. permission to use your personal information for the purposes of accessing the downloadable material and sales outreach. Detailed rules of the data processing are set out in the Privacy Policy . * - mandatory field pr This site is protected by reCAPT
| BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's dise
Curasen receives investment to advance α1A-AR agonist for Alzheimer’s disease | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's
CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busine … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study October 24, 2025 | 3 min read Twitter LinkedIn Facebook Email Print CuraAX aims to address debilitating blood pressure drops and cognitive symptoms of nOH SAN CARLOS, Calif.--(BUSINES … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CuraSen Therapeutics - Pappas Capital Aktis Oncology Reports First-in-Human Clinical Imaging… BOSTON, May 21, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including... Read More Investor Login Toggle navigation Home About About Us News & Events For Entrepreneurs Contact Us Team Portfolio Ventures Specialized Fund Management About Chiesi Ventures Fund Asia Innovation Ventures AgTech Initiatives Specialized Holdings Trans
CuraSen treats first subject in nOH trial of CuraAX Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Services Compa
Curasen Therapeutics Inc. | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events … PhD | California, United States CST-3056 - CNS Optimized α1A-AR Partial Agonist Proposal for AD and Related Diseases Millions of patients are burdened by AD, yet no new therapeutics have evolved to improve symptoms, let alone slow progression, despite two decades of intensive R&D. Approved older drugs marginally reduce cognitive symptoms, with limited response durability. At CuraSen, we contend that these failures to treat complex brain diseases derive from well-intention … tinct agonists (CST-103 and CST-2032). The second is the subject for this proposal, supporting preclinical and clinical advancement of a novel α 1A -AR agonist, CST-3056. View all funding to this organization (1) View all funding to this investigator (1) GET IN TOUCH [email protected] 212.901.8000 Alzheimer's Drug Discovery Foundation A GuideStar-Rated Charity 57 West 57th Street, Suite 904 New York, NY 10019 [email protected] 212.901.8000 © Copyright 202 … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities Diagnostics Accelerator Melvin R. Goodes Prize
Home | CuraSen About Leadership Science Pipeline Careers News Contact Think, Again Rethinking Brain Disease © 2026 by CuraSen Therapeutics, Inc. MENU About Leadership Science Pipeline Careers News Contact
Robert F. Booth PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Robert F. Booth PhD Co-Founder and Advisor at CuraSen Therapeutics, Inc. Robert F. Booth PhD 's Executive Work History Current Advisor , Advisor Equilar on 02/23/2026 Epirium Bio, Inc. Advisor , Advisor Equilar on 10/14/2025 PRIME MOVERS LAB LLC Boa